<DOC>
	<DOCNO>NCT00326885</DOCNO>
	<brief_summary>The purpose study determine whether investigational drug catumaxomab safe effective treatment recurrent symptomatic malignant ascites .</brief_summary>
	<brief_title>Study Trifunctional Antibody Catumaxomab Treat Recurrent Symptomatic Malignant Ascites</brief_title>
	<detailed_description>A multi-center , phase II study catumaxomab ovarian cancer patient recurrent symptomatic malignant ascites require therapeutic paracentesis . Each eligible patient receive four ascend dos catumaxomab , administer intraperitoneally via indwell catheter . Catumaxomab administer 3-hour constant rate infusion dose interval 3-4 day . Each patient participate study 7 month ( include baseline therapeutic paracentesis screen period , 11 21 day treatment period , 180 days/6 month follow-up ) , monthly post-study follow-up lifetime patient . Catumaxomab trifunctional antibody target EpCAM tumor cell CD3 T cell . Trifunctional antibody represent new concept target anticancer therapy . This new antibody class capability redirect T cell accessory cell ( e.g . macrophage , dendritic cell ( DCs ) natural killer ( NK ) cell ) tumor site . According preclinical data , trifunctional antibody activate different immune effector cell , trigger complex anti-tumor immune response .</detailed_description>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Signed date informed consent Histologically confirm diagnosis epithelial ovarian cancer , peritoneal cancer , fallopian tube cancer ; stage diagnosis [ International Federation Gynecology Obstetrics ( FIGO ) Stages I IV ] . Progression ≤ 12 month primary platinumbased systemic intraperitoneal ( IP ) chemotherapy OR relapse follow reinduction ≥ 12 month primary chemotherapy . Have refuse , fail , deem suitable candidate gemcitabine liposomal doxorubicin . Recurrent symptomatic malignant ascites require therapeutic paracentesis At least 1 therapeutic paracentesis within 4 week prior baseline paracentesis Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Life expectancy ≥ 16 week Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN , total bilirubin ≤ 1.5 x ULN Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 platelet count ≥ 75,000/mm3 Negative serum pregnancy test result screen woman childbearing potential ( applies patient without document menopause sterility ) . Willingness patient childbearing potential use effective contraceptive method ( i.e. , oral contraceptive , cervical cap , diaphragm spermicide , condom spermicide , intrauterine device ) study least 6 month last infusion . Acute chronic systemic infection Exposure investigational drug , chemotherapy radiotherapy 21 day prior first dose catumaxomab Major surgery 2 week prior first dose Previous treatment mouse rat antibody Known suspect hypersensitivity catumaxomab monoclonal antibody Body mass index ( BMI ) &lt; 19 ( body weight paracentesis use calculation BMI ) Serum albumin level &lt; 2.0 g/dL Reduced nutritional status require predominantly parenteral nutrition ( &gt; 50 % energy intake ) . Permanent nasogastric ( NG ) feed tube . Ileus location precludes paracentesis Extensive liver metastasis ( &gt; 70 % organ volume comprises malignancy ) Documented brain metastasis History myocardial infarction , congestive heart failure relevant cardiac arrhythmia 3 month prior first dose catumaxomab Portal vein obstruction portal vein thrombosis diagnose compute tomography ( CT ) scan screen Persistent massive pleural effusion inadequate respiratory function etiology ( except relate ascites symptom ) opinion investigator Any condition , accord investigator , result undue risk patient participate study Prior exposure catumaxomab</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ascites</keyword>
	<keyword>Epithelial Cancer</keyword>
	<keyword>Epithelial Carcinoma</keyword>
	<keyword>Epithelial Ovarian Cancer</keyword>
	<keyword>Epithelial Ovarian Carcinoma</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>Fallopian Tube Carcinoma</keyword>
	<keyword>Malignant Ascites</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Ovarian Carcinoma</keyword>
	<keyword>Ovarian Epithelial Cancer</keyword>
	<keyword>Ovarian Epithelial Carcinoma</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Peritoneal Carcinoma</keyword>
	<keyword>Recurrent Ascites</keyword>
	<keyword>Recurrent Malignant Ascites</keyword>
	<keyword>Recurrent Symptomatic Malignant Ascites</keyword>
	<keyword>Symptomatic Malignant Ascites</keyword>
	<keyword>Symptomatic Ascites</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>Ovarian Neoplasms</keyword>
	<keyword>Fallopian Tube Neoplasms</keyword>
	<keyword>Peritoneal Neoplasms</keyword>
</DOC>